Fulcrum Therapeutics(US:FULC)2025-07-29 12:34Financial Performance - The company ended Q2 2025 with $214.1 million in cash, cash equivalents, and marketable securities, down from $241.0 million at the end of 2024, primarily due to cash used for operating activities [10]. - Collaboration revenue was zero for Q2 2025, a decrease of $80.0 million compared to the same period in 2024, which included an upfront license payment from Sanofi [10]. - The net loss for Q2 2025 was $17.3 million, compared to a net income of $55.4 million in Q2 2024 [10]. - Research and development expenses decreased to $13.0 million in Q2 2025 from $17.3 million in Q2 2024, attributed to reduced employee compensation costs and the discontinuation of the losmapimod program [10]. - General and administrative expenses were $6.8 million for Q2 2025, down from $10.2 million in Q2 2024, due to decreased professional services and employee compensation costs [10]. Clinical Development - Fulcrum reported a robust mean increase of 8.6% in fetal hemoglobin (HbF) from the 12 mg dose cohort of the PIONEER trial, with a mean of 67% F-cells observed [4]. - Fulcrum plans to provide clinical data from the 20 mg dose cohort of the PIONEER trial by the end of 2025 [4]. - The company is advancing its program for inherited aplastic anemias and plans to submit an IND for Diamond-Blackfan anemia in Q4 2025 [4]. - Pociredir has been granted FDA Fast Track designation and Orphan Drug Designation for the treatment of sickle cell disease [8]. Cash Management - Fulcrum's cash runway is projected to extend into 2028 based on current operating plans [6].